Kornimate/medical-research-clean huggingface dataset:
intense regulated pulse light therapy in dry eye disease

Conditions: Dry Eye Disease

Summary: the aim of this study is to assess the effect of intense regulated pulse light (irpl) on the treatment of dry eye.

dry eye disease is a common ocular condition that needs prompt diagnosis and careful treatment interventions. if left untreated, it can lead to numerous sight threatening complications, including ulceration of the cornea, blepharitis, alterations of the tear film, conjunctivitis, and in severe cases, significant drying of the eye may lead to scarring, thinning, and even perforation of the cornea. intense pulsed light (ipl) therapy is a new treatment strategy for treatment of mgd by inducing the restoration of the normal activity of the meibomian glands. in fact, ipl has been used for treating the patients with facial telangiectasias and erythema of rosacea and also resulted in improvement in ocular surface health. evaporative form is the commonest form of ded and it is mainly caused by meibomian glands dysfunction (mgd). the usual traditional treatment options for mgd include warm compresses, expression of meibomian glands (mg), anti-inflammatory drugs, and lubricant eye drops. the aim of this study is to assess the effect of intense regulated pulse light (irpl) on the treatment of dry eye. the study included 34 patients with moderate to severe evaporative dry eye. the symptoms will be assessed with the dry eye-related quality of life score (deq-5) questionnaire. the tear film will be assessed through mediworks d130+s390l (wdr) which is a device attached to the slit lamp for non-invasive examination of tear film. patients will be divided into 2 groups: the 1st group include (17) patients who will be treated with intense regulated pulse light (irpl) \& the 2nd group include (17) patients will treated by traditional methods of mgd as eyelid hygiene, topical lubricant, topical \& systemic antibiotics \& anti-inflammatory agents irpl will be done using e-eye (e-swin, france) \& each patient will undergo 3 sessions on day (1), day (15), and day (45). the patients will be reassessed after the 3rd session.

Eligibility criteria:
inclusion criteria: * patients with moderate to severe dry eye disease \& clinicaily significant signs of meibomian gland dysfunction exclusion criteria: * use systemic medications known to affect the eye two weeks prior to baseline assessment. * pregnancy. * ocular surgery or dermatologic treatments in the previous two months or during the treatment period. * implants, tattoos, or pigmented lesions in the treatment area. * contraindications to ipl therapy, including the use of photosensitive medications.

Keywords: ipl therapy irpl therapy dry eye mgd
ex vivo-expanded regulatory t cells plus low-dose interleukin-2 for steroid-refractory chronic gvhd

Conditions: Graft Versus Host Disease (cGvHD)

Summary: hematopoietic stem cell transplant (hct) has been used to treat children and adults who have leukemia, lymphoma and other cancers of blood and immune cells since the 1970s. for many of these forms of cancer, hct works well. however, hct can cause serious, sometimes life-threatening complications. one of the most serious and common complications of hct is graft-versus-host disease (gvhd). gvhd can appear early after the transplant, usually about 3 to 4 weeks after the transplant is given. this is called acute gvhd (agvhd), because it usually happens over a couple of days. if successfully treated, acute gvhd quickly goes away. sometimes gvhd happens months after the transplant. then it is called chronic gvhd (cgvhd), because it happens gradually and goes away slowly. the investigators are doing this study to see if one dose of ex vivo-expanded regulatory t cells (eve-treg) can be used together with the daily interleukin 2 (il-2) to treat cgvhd, that has not responded to steroid treatment or low-dose il-2.


Eligibility criteria:
inclusion criteria: * recipient of 7-8/8 hla-matched allogeneic hematopoietic stem cell transplantation or recipient of haploidentical allogenic hematopoietic stem cell transplantation. * age 2 and up. * must have steroid-refractory chronic gvhd that is still active despite at least 4 weeks of treatment with low-dose subcutaneous (sc) il-2. * stable dose of glucocorticoids for 2 weeks prior to enrollment * no addition or subtraction of other immunosuppressive medications for 4 weeks prior to enrollment. * must have adequate organ and marrow function. * ability to understand and willingness to sign a written informed consent form. * donor who is willing and cleared to donate starting material for manufacture of eve-treg. exclusion criteria: * recipient of umbilical cord blood stem cell graft. * ongoing prednisone requirement greater than 1 mg/kg/day (or equivalent). * karnofsky/lansky performance score less than 40%. * concurrent use of methotrexate, azathioprine, or a calcineurin-inhibitor plus sirolimus. * other investigational agents within 4 weeks prior to enrollment. * participants with post-transplant exposure to donor lymphocyte infusion, or t-cell or il-2 targeted medications within 100 days prior to enrollment. * participants with new immunosupprssive medication, extra-corporeal photopheresis or rituximab therapy initiated int he 4 weeks prior to enrollment. * participants with active malignant relapse or recrudescence of their prior hematologic disorder. * uncontrolled intercurrent illness unrelated to cgvhd. * participants with psychiatric illness/social situations that would limit compliance with study requirements. * pregnant patients are excluded.
postural effects of being rotated in a whole body gyroscope

Conditions: Falls; Balance; Movement Disorders

Summary: subjects will be secured and rotated in a whole body gyroscope, similar to a flight trainer for astronauts. the rotations will be in many directions and the speed will be at 90 deg/sec. the effects of this rotation on the ability to stand upright will be measured.

computerized dynamic posturography (cdp) testing will be obtained after practice sessions on all subjects using a caps pro system (vestibular technologies, cheyenne wy, usa). all tests will be conducted with the subject standing on a perturbing foam cushion. six different conditions will be tested in sequence without the subjects stepping away from the foam/platform in order to assess if the center of sway position changed with the changing test conditions: (1) eyes open head neutral, (2) eyes closed head neutral, (3) eyes closed head right, (4) eyes closed head left, (5) eyes closed head flexed, (6) eyes closed head extended. subjects will be continuously rotated in a computer-controlled multi-axis chair (gyrostim by ultrathera technologies, inc.) in combinations of whole body pitch and yaw simultaneously over a 40 second profile at 90 deg/sec (15 rpm). the acceleration rates to 90 degrees per second as well as deceleration rates will be linear and occur in 1 second. we will utilize rotations that will represent all combinations of pitch and yaw with pitch direction changing two times and yaw direction four times (backward pitch -20 seconds with right yaw-10 seconds to left yaw-10 seconds, to forward pitch- 20 seconds with right yaw-10 seconds to left yaw 10 seconds). post rotational cdp testing will be compared to the pre rotational cdp,

Eligibility criteria:
inclusion criteria: * normal healthy adults without a history of vertigo or dizziness exclusion criteria: * history of dizziness or vertigo

Keywords: posturography balance falls gyroscope rotational chair vestibular movement disorders
efficacy and safety of oral acarbose treatment in patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to evaluate the efficacy and safety of acarbose in type 2 diabetic patients using two different formulations of acarbose 50mg.

study design: * multicenter * phase iii * randomized * double blind * prospective and comparative * experiment duration: 105 days * 5 visits * efficacy * adverse event

Eligibility criteria:
inclusion criteria: * patients must be able to understand the study procedures agree to participate and give written consent. * diagnosed with type 2 diabetes mellitus (t2dm)b * female patients of childbearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) which agree to use a medically accepted contraceptive regimen for the duration of the study. exclusion criteria: * pregnancy or risk of pregnancy. * lactation * any pathology or past medical condition that can interfere with this protocol * other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation. * known hypersensitivity / intolerance to acarbose or any of its excipients
short and ultra-short-pulse nd: yag 1064nm lasers (omer smart and omer premium) for stasis dermatitis

Conditions: Stasis Dermatitis

Summary: this study tests two types of lasers (nd yag 1064 short and ultra-short pulses) to treat hyperchromic skin lesions secondary to venous hypertension (stasis dermatitis)

background: stasis dermatitis with hyperpigmented skin lesions is a serious health problem for patients with chronic venous hypertension. although no randomized studies have evaluated lasers for this treatment, lasers can be an attractive option. methods: this prospective, randomized, 3-arm, open-label, vehicle-controlled study will enroll patients scheduled to undergo treatment for stasis dermatitis with hyperpigmented skin lesions. patients will be allocated to either nd: yag 1064 nm short pulse laser-nanoseconds (group 1), or nd: yag 1064 nm ultra-short-pulse laser-picoseconds (group 2), or cold cream vehicle control (group 3). all treatments are scheduled for 6 visits with pre-defined dates, with a final follow-up visit at intervals of 28 to 35 days. primary outcomes include colorimetry analysis, secondary outcomes pre- and post-photographic analysis, and dlqi quality-of-life assessment. conclusions: the results of this trial will provide high-quality evidence to guide clinical practice on optimal management of hyperpigmented skin lesions secondary to stasis dermatitis.

Eligibility criteria:
inclusion criteria: 1. women or men aged 18 to 89 years with stasis dermatitis secondary to venous hypertension 2. agreement with the terms of the survey and signing of the informed consent form 3. availability to make the necessary appointments for treatment and follow-up 4. provide consent to avoid pregnancy during treatment 5. have primary venous hypertension already treated (treatment of varicose veins of the lower limbs) by any of the available techniques exclusion criteria: 1. men and women with ceap 2 to 6, low mobility, no stasis dermatitis. 2. peripheral arterial disease. 3. history of known allergy to the drugs used in this study 4. presence of other types of dermatitis in the lower extremities, such as allergic stasis eczema. 5. presence of comorbidities (such as diabetes mellitus, heart failure, respiratory failure, hypertension, hypothyroidism, or hyperthyroidism), pregnancy, breastfeeding, pulmonary hypertension, deep vein thrombosis (dvt), family history of dvt, known hypercoagulable states or thrombophilia, asthma, and migraine. 6. anyone who does not agree with any of the search terms. -

Keywords: laser stasis dermatitis hyperchromic skin lesions
evaluate the quality of life of patients with amd

Conditions: Age-related Macular Degeneration

Summary: age-related macular degeneration (amd) is a major cause of deep visual acuity loss. because of progressive deterioration of the macula, patients with amd complain about progressive visual problems that can impair their quality of life in the physical, mental and social domains. the principal objective principal of this study is to describe the evolution of quality of life between the diagnosis of secondary atrophic amd and at 18 months after confirmation of diagnosis.


Eligibility criteria:
inclusion criteria: - for the 2 populations studied * persons who have given consent to take part * persons aged 50 years or older * willing and able to attend all of the scheduled visits and evaluations * macular atrophy or drusen measuring at least 125μm or multiple drusens measuring at least 63μm * atrophic amd diagnosed on oct and by autofluorescence and oct angiography by 2 independent experienced assessors * diagnosed for less than 3 years * mavc score ≥ 19 letters (equivalent snellen ≥ 20/400), by using a scale at an initial distance of 4m for patients with secondary atrophic amd • secondary atrophic amd, defined by persistent atrophic amd at 1 year after the last injection of an anti-angiogenic agent, and at least 2 years after the first injection. exclusion criteria: general criteria * persons without national health insurance cover * physical or mental disability ruling out participation * inability to sign the written consent form, adults under guardianship * any participation in a study involving an experimental drug during the previous 3 months (dietary supplements are authorised). * adults under guardianship general medical history • uncontrolled aht ophthalmological history * severe non-proliferative or proliferative diabetic retinopathy * uncontrolled glaucoma (defined as an intra-ocular pressure greater than 30mmhg despite treatment with an anti-glaucoma agent) or a history of filtration surgery * corneal disease that could impair vision * monogenic macular dystrophy or toxic maculopathy * history of uveitis * amblyopia of the eye concerned * intraocular surgery in the 3 months preceding inclusion * history of cornea transplantation in the studied eye * treatment affecting vision: chloroquine and hydroxychloroquine, phenothiazine, tamoxifen, interferon (93), external radiotherapy of the face and neck ophthalmological examination * significant cataract (locs iii grade of 5 or above, annexe 5.) (94) * active infection in either eye * central anterior serous or active retinopathy in either eye * choroid neo-vascularisation * active serous retinal detachment * refractive error less than -15d or more than +10d
brucella serology and history of brucellosis in patients with modic changes type 1

Conditions: Brucellosis; Spinal Degeneration

Summary: objective: this study aims to examine brucella serology and history of brucellosis in patients with lumbar modic changes (mcs) type 1, considering results from cross-sectional and case-control comparisons. design: in comparative cross-sectional design, mcs type 1 patients (study group) and mcs type 2 patients (comparator group) were examined in terms of brucella serology by using agglutination with coombs test. in addition, in comparative case-control design, both of the mcs groups and age/sex-matched healthy controls were investigated for their medical history regarding brucellosis.


Eligibility criteria:
inclusion criteria: * patients with lumbar modic changes type 1 * patients with lumbar modic changes type 2 * participant who given informed consent for the study exclusion criteria: * patients aged\<18 years * history of serious lumbar trauma * lumbar spinal surgery * scoliosis * cooperation disorder
effects of aging and gender-affirming hormone therapy on vascular endothelial function and metabolic profiles in transgender women

Conditions: Transgender; Gender Identity; Vascular Stiffness; Vascular Inflammation; Insulin Sensitivity; Blood Pressure; Lipid Disorder; Appetitive Behavior

Summary: this study will examine markers of vascular endothelial function (vascular health) and metabolic profiles in younger versus older transgender women (people who were assigned male at birth but whose gender identity is female). data will also be compared to those from cisgender women and men.


Eligibility criteria:
inclusion criteria: * aged 18-40 years old or 50-75 years old * identify as a transgender woman * have taken estradiol and spironolactone for at least one year * currently taking oral or transdermal estradiol exclusion criteria: * don't identify as a transgender woman * not currently taking estradiol or spironolactone * have been on estradiol and spironolactone for less than one year * history of orchiectomy * current tobacco smoker * current illicit drug use * history of prior or active estrogen-dependent neoplasms * acute liver or gallbladder disease * venous thromboembolism * hypertriglyceridemia \>500 mg/dl * fasted plasma glucose \>7.0 mmol/l or previously treated diabetes * resting blood pressure \>140/90 mmhg
the role of nitazoxanide, interferon alfa and ribavirin in treatment of hepatitis c infected type 2 diabetic patients

Conditions: Hepatitis C, Chronic; DIABETES MELLITUS Type 2

Summary: the purpose of this study is to investigate if nitazoxanide used in combination with interferon alfa and ribavirin is effective in treating hepatitis c infected type 2 diabetic patients by improving their sustained viral response by more than 80%.considering that the study is being conducted in a third world country like pakistan, the standard treatment of hepatitis c is not cost effective. the aim is to introduce a new treatment comparable in efficacy to peginterferon and also cost effective.

after taking proper informed consent from patients, patients who fulfill the research criteria are randomized into 2 groups (control/study). patients in both groups will be treated with conventional interferon alfa and ribavirin.those in study group will be given tab nitazoxanide 500mg twice daily in addition to conventional treatment. the patients will be followed up at regular intervals: 0,4,12,24,48 week.at each visit hepatitis c virus(pcr)rna, liver function tests, complete blood count will be done.

Eligibility criteria:
inclusion criteria: * hepatitis c genotype 3a * hepatitis c virus(pcr)rna detected * alanine transaminase \>60 * diabetic hba1c\<8 * bmi\>23 exclusion criteria: * previously treated hepatitis c patients * pregnant females * decompensated liver disease,child class b or above * thyroid disease,thyroid stimulating hormone\>10,0.05 * absolute neutrophil count\<1500,platelets\<80,000,hb\<10g female,\<11g male * severe cardiac disease,new york heart association2 * moderate to severe depression assessed by beck depression inventory scale

Keywords: nitazoxanide, sustained viral response type 2 diabetics
evaluation of an individually tailored digital service to promote healthy and sustainable behaviors and well-being

Conditions: Well-being

Summary: the goal of this quasi-experimental observational study is to evaluate the impact of an individually tailored digital service aimed to support healthy habits on well-being, lifestyle behaviors, and mental health among the adult population. the main questions it aims to answer are: i) is a digital service developed to personalize support for healthy habits effective in improving well-being compared to a control group in the general population after 6 months? ii) does the digital service improve dietary and physical activity habits, mental health, and well-being among users across 24 months? iii) are sociodemographic factors associated with achieving the self-identified goals and improvements in dietary and physical activity habits, mental health, and well-being? iv) do the intended mediators (engagement with the service, improved motivation, improved self-efficacy, and reduced barriers) mediate the effects of the digital service on achieving the self-identified goal, improved dietary and physical activity habits, mental health, and well-being? v) how is the pattern of user engagement across 24 months? participants are users of the mobile phone application longlife active®. researchers will compare with individuals in the general population to see if the digital service is effective in improving well-being, dietary and physical activity habits, and mental health.

longlife active is an individually tailored digital service supporting healthy habits that is based on behavioral research evidence, supported by artificial intelligence and co-developed.

Eligibility criteria:
inclusion criteria (intervention arms): * adults ≥18 years * siging up for the service longlife active using bankid for identification * consent to the research study inclusion criteria (controls): * adults ≥18 years * consent to the research study exclusion criteria (intervention arms): * individuals who are discharged from the app due to refracting the terms of the service * subjects scoring \>70 on well-being will be excluded from the primary analyses exclusion criteria (controls): * age ≤ 17 years. * is currently using a digital product or any other kind of support for behavior change * is found to be a user of longlife active. * subjects scoring \>70 on well-being will be excluded from the primary analyses

Keywords: primary prevention secondary prevention health promotion self-management behavior
abraxane and temodar plus genasense in advanced melanoma

Conditions: Melanoma

Summary: this study is designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of combination treatment with temodar®, genasense®, and abraxane® in chemotherapy-naïve subjects with advanced melanoma and normal lactate dehydrogenase (ldh).


Eligibility criteria:
inclusion criteria: * subjects with progressive, unresectable, or advanced melanoma who are considered to be candidates for systemic treatment with chemotherapy * subjects will have measurable disease, an eastern cooperative oncology group performance status less than or equal to 2, and serum ldh less than or equal to 1.1 times the upper limit of normal, but will not have previously received cytotoxic chemotherapy * prior immunotherapy, radiotherapy, or cytokine, biologic, or vaccine therapy is permitted in the adjuvant and/or metastatic setting exclusion criteria: * prior treatment with cytotoxic chemotherapy, including regional perfusion, or with genasense®(oblimersen sodium)injection * nonmeasurable disease only * history or presence of brain metastasis or leptomeningeal disease * significant medical disease other than cancer * known human immunodeficiency virus infection * pregnant or lactating * known hypersensitivity to temozolomide, phosphorothioate-containing oligonucleotides, or products containing human albumin * use of any experimental therapy within 3 weeks prior to baseline evaluations, other anticancer treatment (such as chemotherapy, radiation, or biologic or investigational therapies) while receiving therapy in this study

Keywords: advanced melanoma normal baseline ldh chemotherapy naive
dose ranging study with lt, monotherapy, ppar

Conditions: Diabetes Mellitus II

Summary: a randomized, double-blind, dose-ranging, dose comparison-controlled trial to determine the safety and efficacy of bms-298585 in subjects with type 2 diabetes


Eligibility criteria:
inclusion criteria: * 1. hba1c \> 7.0% and ≤ 10.0% obtained at the screening visit. * 2. men and women, 18-70 years of age established type 2 diabetes exclusion criteria: * 1. symptomatic type 2 diabetes defined as marked polyuria and polydipsia with greater than 10% weight loss during the last three months. * 2. administration of antihyperglycemic agents (other than thiazolidinediones) for more than three consecutive or a total of seven non-consecutive days during the four weeks prior to screening. * 3. administration of thiazolidinediones for more than three consecutive or a total of seven non-consecutive days during the six weeks prior to screening.